Practical Guidance on Mental Health and Physician Burnout
Latest News
‘Exciting’ New Therapies, Including BTK Inhibitors and Monoclonal Antibodies, Promising for CLL
In recent years, the treatment of chronic lymphocytic leukemia (CLL) has undergone a seismic shift, with chemotherapy being replaced by a new and more effective generation of drugs. One of the "really exciting" therapies to emerge is the Bruton's tyrosine kinase inhibitors.
Learn MoreObinutuzumab Plus Venetoclax Produces Significant Survival Benefits in CLL
For decades, chemotherapy was the foundation of treatment for chronic lymphocytic leukemia (CLL). Today, monoclonal antibodies like obinutuzumab have become part of the standard of care for CLL patients.
Learn MoreCAR T-Cell Therapy is a ‘Revolution in Cancer Immunotherapy’
Chimeric antigen receptor (CAR) T-cell therapy is "paradigm changing" -- a "revolution in cancer immunotherapy." This treatment has ushered in a new era of therapy for blood cancer patients.
Learn MoreTo Treat Ovarian Cancer With PARP Inhibitors or Not: Factoring the Progression-Free Survival Benefit and Side Effects Into the Decision
PARP inhibitors like niraparib (Zejula) are an effective tool against ovarian cancer. The NOVA trial established that niraparib as maintenance therapy in platinum-sensitive patients significantly improved progression-free survival compared to placebo, regardless of women's BRCA or homologous recombination deficiency (HRD) status. Then, the PRIMA study found the treatment extended PFS in patients with newly diagnosed ovarian cancer, with or without HRD deficiency.
Learn MoreCAR T-Cell Therapy is ‘Exciting,’ But Also ‘Overwhelming’ for Patients
Chimeric antigen receptor (CAR) T-cell therapy has been transformative in blood cancer therapy, particularly for patients with previously poor outcomes; however, producing the CAR T cells can be a complex process.
Learn MorePatients Need Careful Monitoring for CAR T-Cell Therapy Side Effects
Chimeric antigen receptor (CAR) T-cell therapy has become a major ally in the treatment of certain lymphomas and leukemias. However, this therapy is not without risks.
Learn MoreThe Promise of CAR T-Cell Therapy for Multiple Myeloma
Chimeric antigen receptor (CAR) T-cell therapy is showing great promise in multiple myeloma, with response rates in studies of 85% or more, and about half of patients going into complete remission for a year or longer.
Learn MoreCytokine Release Syndrome: The Downside of CAR T-Cell Therapy
Chimeric antigen receptor (CAR) T-cell therapy has had great success thus far, producing lasting responses and even remissions in patients with relapsed or refractory hematologic cancers such as B-cell lymphoma and acute lymphoblastic leukemia (ALL).
Learn More